Kingmed Diagnostics boosts related-party transaction forecast, posts Q3 loss

Kingmed Diagnostics Group announced an adjustment to its 2025 estimated daily related party transaction amount with KingCreativity Biotechnology Co., Ltd., increasing it from 205 million yuan to 240 million yuan. This adjustment, approved by the board on October 29, 2025, primarily relates to the procurement of instruments and consumables, reflecting higher-than-anticipated demand. The transactions are considered to be in the ordinary course of business and conducted on fair market terms.

Concurrently, the company reported a net loss of 88,794,076.93 yuan for the first nine months of 2025, with third-quarter net income attributable to shareholders at 5,197,288.53 yuan, a 24.08% increase year-on-year. This comes amidst a significant provision for asset impairment and credit losses totaling 345,263,020.04 yuan for the same period. Separately, major shareholder Guochuang Kaichuang Private Equity Investment Fund (Limited Partnership) confirmed no shares were sold during its planned reduction period, which concluded on October 29, 2025.